Latest news for Quantum Cap (OTC:QTCI) Stock

Quantum Capital Inc is an Australian company. The company owns Loan Base Pty Ltd, an Australian company with the mission of providing clients with personalized lending solutions that achieve their goals through premium, online, exclusive, convenient, and tailored lending solutions intermediary platforms.

Equities

News

Penny Stocks

Markets

General

QTCI

REPYY

Repsol S.A.(OTC: REPYY) joins the U.S. onshore wind market by acquiring renewable energy platform ConnectGen, with a 20,000 MW pipeline and development capabilities, for $768 million. 

Repsol Dives Into US Wind Market With ConnectGen Acquisition Worth $768M

QUANTUM CAPITAL INC by Quantum Capital Inc.

Quantum Capital Inc

Guidance

Citigroup Sees FY25 Revenue $83.5B-$84.5B Vs $83.24B Est

Morgan Stanley analyst Ronald Kamdem upgrades CBRE Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) from Equal-Weight to Overweight and raises the price target from $115 to $160.

Upgrades

Price Target

Analyst Ratings

CBRE

Morgan Stanley Upgrades CBRE Group to Overweight, Raises Price Target to $160

Mercurity Fintech Holding Inc. (the "Company," "we," "us," "our company," or "MFH") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>), a digital fintech group, is pleased to announce the pricing of another private investment in public equity (the "PIPE") financing. On January 9, 2025, the Company entered into a securities purchase agreement and priced the PIPE offering, pursuant to which it sold an aggregate of 1,370,000 ordinary shares to one institutional investor at a price of US$5.87 per share. The financing is priced at-the-market under Nasdaq rules, representing 100% of the closing price of the Company's shares on January 8, 2025. The offering resulted in total gross proceeds of approximately US$8,041,900 ("Gross Proceeds") before deducting fees and offering expenses payable by the Company.
Subject to customary closing conditions, the PIPE is expected to close on or before January 17, 2025. The securities described above were sold in a private placement and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the "SEC") or an applicable exemption from such registration requirements.
This PIPE investment comes just weeks after the Company's successful closing of a previous US$10 million PIPE offering with the same institutional investor on December 19, 2024, at US$6.81 per share.

Offerings

Mercurity Fintech Announces The Pricing Of Another Private Investment In Public Equity Financing. On January 9, 2025, The Company Entered Into A Securities Purchase Agreement And Priced The PIPE Offering, Pursuant To Which It Sold An Aggregate Of 1.37M Ordinary Shares To One Institutional Investor At A Price Of $5.87 Per Share

LUXH

LuxUrban Sees 2025 Revenue $62M-$67M

Genius Sports Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) ("Genius Sports," the "Company," "we" or "our") announced today the pricing of an underwritten public offering of 17,647,059 ordinary shares, par value $0.01 (the "Ordinary Shares"), by the Company at a price to the public of $8.50 per Ordinary Share. The offering is expected to close on January 16, 2025, subject to the satisfaction of customary closing conditions.
The Company estimates the net proceeds from the offering will be approximately $144 million, after deducting the underwriting commissions and estimated offering expenses. The Company currently expects to use the net proceeds from this offering for general corporate purposes, which may include the acquisition or investment in complementary businesses, technologies or other assets, although the Company currently has no agreements or understandings with respect to any such acquisitions or investments.
The offering included participation from Caledonia and Wellington Management, among other top existing shareholders as well as new investors.

GENI

Genius Sports Announces Pricing Of $144M Public Offering Of 17,647,059 Ordinary Shares At A Price To The Public Of $8.50 Per Ordinary Share

WIIM

Citigroup shares are trading higher after the company reported better-than-expected Q4 financial results and announced a $20 billion buyback

Johnson & Johnson Initiates Submission Of New Drug Application With FDA For TAR-200 In BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer

<ul>
<li>ENVISION Reports 79.6% Complete Response Rate at 3 Months, 82.3% Duration of Response at 12 Months, and Consistent Safety Profile</li>
</ul>
UroGen Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the 3-month complete response (CR) rate and 12-month durability of response from the Phase 3 ENVISION study of investigational drug UGN-102 in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) were published in the February issue of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.auajournals.org%2Fdoi%2F10.1097%2FJU.0000000000004296&amp;esheet=54180006&amp;newsitemid=20250115929797&amp;lan=en-US&amp;anchor=The+Journal+of+Urology&amp;index=1&amp;md5=45dddb06f66d1cd53513343d492a0608">The Journal of Urology</a>.
In the ENVISION trial, UGN-102 treatment demonstrated an impressive 82.3% (95% CI, 75.9%, 87.1%) 12-month duration of response (DOR) by Kaplan-Meier estimate (n=108) in patients who achieved a CR at three months after the first instillation of UGN-102 (mitomycin) for intravesical solution. The Kaplan-Meier estimates for DOR at 15 months (n=43) and 18 months (n=9) following the 3-month CR were both 80.9% (95% CI, 73.9%, 86.2%). The ENVISION trial also met its primary endpoint, showing a 79.6% (95% CI, 73.9%, 84.5%) CR rate at three months in patients treated with UGN-102.

Biotech

URGN

UroGen Pharma Reports ENVISION Trial Results Published In The February Issue Of The Journal Of Urology Highlight UGN-102 Achievement Of 82.3% Duration Of Response at 12 Months Paving The Way For The Potential First FDA-Approved Treatment For LG-IR-NMIBC In June 2025

CERT

Certara Sees Q4 Revenues Of $99.7M, compared to $88M YoY, Sees Q4 Bookings of $144.5M

Northland Capital Markets analyst Michael Latimore maintains Serve Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) with a Outperform and raises the price target from $16 to $23.

SERV

Northland Capital Markets Maintains Outperform on Serve Robotics, Raises Price Target to $23

Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.22 by 9.84 percent. The company reported quarterly sales of $19.58 billion which beat the analyst consensus estimate of $19.48 billion by 0.52 percent. This is a 12.28 percent increase over sales of $17.44 billion the same period last year.

Earnings

Earnings Beats

Citigroup Q4 2024 Adj EPS $1.34 Beats $1.22 Estimate, Sales $19.58B Beat $19.48B Estimate

Ratings for Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.75, with a high estimate of $82.00 and a low estimate of $55.00. Witnessing a positive shift, the current average has risen by 21.3% from the previous average price target of $57.50.
<img src="https://www.benzinga.com/files/images/story/2025/1736946099_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Affirm Holdings is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$78.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>John Hecht</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Bryan Keane</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$75.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Jason Kupferberg</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$74.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$69.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$56.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$57.00</td>
<td>$52.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Affirm Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Affirm Holdings compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Affirm Holdings's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Affirm Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AFRM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Affirm Holdings analyst ratings.</a>
<h2>About Affirm Holdings</h2>
Affirm Holdings Inc offers a platform for digital and mobile-first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a majority share of its revenue from the United States.
<h3>Affirm Holdings's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Affirm Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 40.67% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Affirm Holdings's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -14.35%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Affirm Holdings's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -3.6%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Affirm Holdings's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.02%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.51, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AFRM

Deep Dive Into Affirm Holdings Stock: Analyst Perspectives (12 Ratings)

Throughout the last three months, 5 analysts have evaluated Vericel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCEL#NASDAQ">VCEL</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Vericel, revealing an average target of $62.6, a high estimate of $67.00, and a low estimate of $60.00. This current average has increased by 5.39% from the previous average price target of $59.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1736946087_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Vericel by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$67.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$66.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Caitlin Cronin</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Vericel. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vericel compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Vericel's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VCEL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vericel analyst ratings.</a>
<h2>About Vericel</h2>
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
<h3>Vericel's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Vericel displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 27.04%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1.56%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.36%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Vericel's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.23%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.38, Vericel adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VCEL

Beyond The Numbers: 5 Analysts Discuss Vericel Stock

Across the recent three months, 4 analysts have shared their insights on TrueCar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUE#NASDAQ">TRUE</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $4.62, a high estimate of $5.00, and a low estimate of $4.00. Observing a 8.45% increase, the current average has risen from the previous average price target of $4.26. 
<img src="https://www.benzinga.com/files/images/story/2025/1736946073_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of TrueCar among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Lee Krowl</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$4.00</td>
<td>$3.30</td>
</tr>
<tr>
<td>Marvin Fong</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$4.50</td>
<td>$3.75</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to TrueCar. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of TrueCar compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of TrueCar's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of TrueCar's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TRUE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on TrueCar analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know TrueCar Better</h2>
TrueCar Inc is a data-driven online platform operating on common technology infrastructure, powered by proprietary data and analytics. It also customizes and operates its platform for affinity group marketing partners, including financial institutions like PenFed and American Express; membership-based organizations like Consumer Reports, AARP, Sam's Club, and AAA; and employee buying programs for large enterprises such as IBM and Walmart. TrueCar enables users to obtain market-based pricing data on new and used cars, and to connect with its network of TrueCar Certified Dealers.
<h3>Breaking Down TrueCar's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, TrueCar showcased positive performance, achieving a revenue growth rate of 13.12% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: TrueCar's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -12.53%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): TrueCar's ROE stands out, surpassing industry averages. With an impressive ROE of -4.29%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): TrueCar's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.33% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: TrueCar's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TRUE

4 Analysts Assess TrueCar: What You Need To Know

<ul>
<li>Trial remains on track for completion and data readout in the second half of 2025 &nbsp;</li>
</ul>
COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology&#x2122; powered vaccines, has now completed the dosing of all 16 patients in its phase 2 trial with the company's lead asset EVX-01. Designed with Evaxion's AI-Immunology&#x2122; platform, EVX-01 is a personalized cancer vaccine being developed as a treatment of advanced melanoma (skin cancer).
Dosing has been completed according to trial protocol and timelines, meaning the trial remains on track for completion and data readout in the second half of 2025. Coincidently, the first patient has now completed the trial and has had last visit according to the protocol. Patients will continue to be monitored and data collected.

EVAX

Evaxion Completes Dosing In Phase 2 Trial With Personalized Cancer Vaccine EVX-01; Trial Remains On Track For Completion And Data Readout In The Second Half Of 2025

Jim Cramer has censured Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) amid irregularities in its <a href="https://www.benzinga.com/markets/equities/25/01/42993388/jim-cramer-eyes-quantum-computing-stocks-like-rigetti-after-gamestop-sell-off-warns-against-super-micro-computer-they-are-trying-so-hard-to-walk-it-up-now">accounting</a>, following a barrage of issues it has been facing since June 2024. 
What Happened: Cramer, who is the host of &#8216;Mad Money&#8217; <a href="https://www.cnbc.com/2025/01/14/cramers-lightning-round-super-micro-computer-is-a-sell.html">on</a> CNBC, during his show answered a question about Super Micro Computer and said, "Sell. It doesn't matter, I don't care…Accounting irregularities equal sell."
This goes back to <a href="https://www.benzinga.com/24/11/42082542/supermicro-computer-shares-soar-32-as-it-avoids-nasdaq-delisting-but-analysts-are-not-convinced-heres-whats-coming-next-for-smci">mid-2024</a> when the company first missed filing the Form 10-K with the SEC, the annual financial report for the company's year ending June 30.
Subsequently, the short-seller Hindenburg Research released a damning report on Aug. 27, accusing SMCI of accounting fraud, self-dealing, and sanctions evasion. Following this the company has faced significant turmoil.
Ernst &amp; Young resigned as SMCI&#8217;s auditor on Oct. 30 and the company missed the deadline for filing its Form 10-Q with the Securities and Exchange Commission for the first quarter of fiscal 2025 as well.
SMCI temporarily avoided delisting from Nasdaq in November by appointing BDO USA as its auditor and submitting a compliance plan. However, it was subsequently removed from the Nasdaq 100 index on Dec. 23.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/42995814/billionaire-investor-who-predicted-the-dot-com-crash-25-years-ago-warns-of-another-market-storm-brewing-in-the-us">Billionaire Investor Who Predicted The Dot-Com Crash 25 Years Ago Warns Of Another Market Storm Brewing In The US </a>
Technical Analysis Indicates Selling Pressure On The Stock:
After wading through the flurry of issues in the second half of 2024, its shares have fallen by 65.99% over the last six months. Its price was 0.46% up to $30.67 in premarket hours on Wednesday.
The technical analysis of the company&#8217;s daily moving averages indicates bearish trends for the stock. Tuesday&#8217;s close of $30.53 apiece was below its short and long-term moving averages.
The eight and 20-day moving averages stood at $32.71 and 32.38, whereas, the 50-day average was at $31.75 according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data. The stock price was much below its 200-day simple moving average of $59.49, signaling a bearish trend.
The relative strength index of 43.78 meant that the stock was in a neutral zone and it was neither overbought nor oversold.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073903/smci-tech-chart-1024x576.png" alt="" class="wp-image-734557" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073903/smci-tech-chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073903/smci-tech-chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073903/smci-tech-chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073903/smci-tech-chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073903/smci-tech-chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Apart from Cramer&#8217;s &#8216;sell&#8217; call, the 17 <a href="https://www.benzinga.com/quote/SMCI/analyst-ratings">analysts tracked by Benzinga</a> had a consensus &#8216;hold&#8217; rating on the stock. The average price target of $27.67 between the three latest issues by Goldman Sachs, JP Morgan, and Wedbush implied a 9.97% downside for SMCI.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/SMCI/analyst-ratings"><img loading="lazy" decoding="async" width="948" height="355" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073743/SMCI-ANR-ANR-ANR.png" alt="" class="wp-image-734553" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073743/SMCI-ANR-ANR-ANR.png 948w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073743/SMCI-ANR-ANR-ANR-300x112.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073743/SMCI-ANR-ANR-ANR-768x288.png 768w" sizes="(max-width: 948px) 100vw, 948px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/01/42996490/nordea-parisi-gray-graypoint-load-up-on-marvell-technology-shares-iaim-dilutes-98-in-q4-heres-what-mrvls-technical-analysis-says">Nordea, Parisi Gray, Graypoint Load Up On Marvell Technology Shares, IAIM Dilutes 98% In Q4: Here&#8217;s What MRVL&#8217;s Technical Analysis Says </a></li>
</ul>
Image via Shutterstock

Analyst Color

Market Summary

Downgrades

Technicals

Trading Ideas

SMCI

Jim Cramer Says SMCI Stock Is A 'Sell' Amid Accounting Irregularities: Super Micro Computer Stock Has Fallen 66% In 6 Months — Here's What Technical Analysis Shows

In the latest quarter, 6 analysts provided ratings for Westinghouse Air Brake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $216.33, a high estimate of $226.00, and a low estimate of $205.00. Observing a 7.63% increase, the current average has risen from the previous average price target of $201.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1736946054_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Westinghouse Air Brake by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ken Hoexter</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$226.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Steve Barger</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Justin Long</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Bascome Majors</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$222.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jerry Revich</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Bascome Majors</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$220.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Westinghouse Air Brake. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Westinghouse Air Brake compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Westinghouse Air Brake's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Westinghouse Air Brake's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WAB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Westinghouse Air Brake analyst ratings.</a>
<h2>Get to Know Westinghouse Air Brake Better</h2>
Westinghouse Air Brake Technologies Corp is a provider of value-added, technology-based products and services for the freight rail and passenger transit industries, and the mining, marine, and industrial markets. It provides its products and services through two main business segments, Freight and Transit. The company generates maximum revenue from the Freight segment which manufactures new and modernized locomotives, provides aftermarket parts and services to existing locomotives; provides components to new and existing freight cars; builds new commuter locomotives; supplies rail control and infrastructure products including electronics, positive train control equipment, signal design and engineering services. Geographically, it generates a majority of its revenue from the United States.
<h3>Understanding the Numbers: Westinghouse Air Brake's Finances</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Westinghouse Air Brake's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 4.43%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Westinghouse Air Brake's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 10.63%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Westinghouse Air Brake's ROE excels beyond industry benchmarks, reaching 2.73%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Westinghouse Air Brake's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.51% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Westinghouse Air Brake's debt-to-equity ratio is below the industry average at 0.39, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Westinghouse Air Brake: Insights From 6 Financial Analysts

Ratings for Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $39.0, along with a high estimate of $52.00 and a low estimate of $22.00. A 7.87% drop is evident in the current average compared to the previous average price target of $42.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1736946039_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Regenxbio among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Regenxbio. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Regenxbio compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Regenxbio's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RGNX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Regenxbio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Regenxbio's Background</h2>
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
<h3>Key Indicators: Regenxbio's Financial Health</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Challenges: Regenxbio's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -16.31%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Regenxbio's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -246.3% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Regenxbio's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -18.35%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Regenxbio's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -10.95%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.28.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RGNX

Regenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

Ratings for Sprout Social (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPT#NASDAQ">SPT</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Sprout Social, revealing an average target of $42.33, a high estimate of $55.00, and a low estimate of $29.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 5.58%. 
<img src="https://www.benzinga.com/files/images/story/2025/1736946026_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Sprout Social among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$37.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sprout Social. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Sprout Social compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Sprout Social's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sprout Social's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SPT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sprout Social analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Sprout Social</h2>
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. The firm generates majority revenue from software subscriptions.
<h3>Key Indicators: Sprout Social's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Sprout Social's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 20.0%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Sprout Social's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -16.65% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -11.02%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Sprout Social's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -4.37%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Sprout Social's debt-to-equity ratio is below the industry average at 0.3, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sprout Social Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

Buybacks

Citigroup Announces $20B Buyback

Quantum Cap

Repsol S.A.(OTC:<a class="ticker" href="https://www.benzinga.com/stock/REPYY#OTC">REPYY</a>) joins the U.S. onshore wind market by acquiring renewable energy platform&nbsp;ConnectGen, with a 20,000 MW pipeline and development capabilities, for $768 million.&nbsp;

The acquisition of ConnectGen from Quantum Capital Group is a new milestone in Repsol Renewables&#39; strategy to strengthen its position as a global player in the renewable energy business.

For 2023, the company plans to allocate 35% of its&nbsp;<a class="editor-rtfLink" href="https://www.repsol.com/en/shareholders-and-investors/financial-information/quarterly-results/index.cshtml" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">investments&nbsp;</a>to low-carbon projects. The fiscal contribution stood at &euro;7.343 billion in the year&#39;s first half. Repsol issued most of its investments in the first half of the year to projects in Spain (43%) and the U.S. (39%).

Also Read:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/markets/equities/23/05/32553202/repsol-mulls-selling-49-stake-in-spanish-wind-farm-and-photovoltaic-power-plants" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">Repsol Mulls Selling 49% Stake In Spanish Wind Farm And Photovoltaic Power Plants</a>

Through this transaction, Repsol will add an onshore wind power growth platform in the U.S. that complements Hecate Enegy&#39;s solar &amp; storage development capabilities.

The deal reinforces its international portfolio to support its strategic target of 20,000 MW of installed capacity by 2030.

Also See:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/markets/equities/23/05/32445107/repsol-spreads-footprint-in-italy-with-first-renewable-project" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">Repsol Spreads Footprint In Italy With First Renewable Project</a>

&quot;This transaction is another step in our firm commitment to transforming our industry and becoming a zero net emissions company by 2050, while maintaining our profitable growth, diversification and multi-energy focus and ensuring shareholder returns. The addition of ConnectGen accelerates our commitment to renewable generation in one of the markets with the greatest potential for future growth. In that sense, bringing on board its valuable team of experts is key to ensure our successful future growth with robust profitability in the market,&quot; explains Josu Jon Imaz, CEO of Repsol.

Price Action:&nbsp;REPYY shares closed lower by 0.58% to $15.53 on Thursday.

Comments

Quantum Cap

News

Latest news for Quantum Cap (OTC:QTCI) Stock

Friday, September 08, 2023

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga